Shanghai Miracogen Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Phase 3

Recruiting

Conditions: Advanced or Metastatic Urothelium Cancer

Interventions: Drug: Docetaxel Injection
Drug: MRG002
Drug: Paclitaxel Injection
Drug: Gemcitabine Hydrochloride for Injection
Drug: Pemetrexed Disodium Injection

First Posted Date: 2023-03-06

Last Posted Date: 2023-04-13

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 290

Registration Number: NCT05754853

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Phase 3

Not yet recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: MRG003
Drug: Cetuximab injection
Drug: Methotrexate Injection

First Posted Date: 2023-03-02

Last Posted Date: 2023-03-02

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 180

Registration Number: NCT05751512

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: MRG003+HX008

First Posted Date: 2023-01-18

Last Posted Date: 2023-01-18

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 18

Registration Number: NCT05688605

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: MRG002+HX008

First Posted Date: 2022-04-21

Last Posted Date: 2022-12-01

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 30

Registration Number: NCT05338957

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 2 locations

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Phase 2

Conditions: Breast Cancer With Liver Metastases

Interventions: Drug: MRG002

First Posted Date: 2022-03-03

Last Posted Date: 2022-12-02

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 99

Registration Number: NCT05263869

Locations: 🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Phase 2

Conditions: Advanced or Metastatic Gastroesophageal Junction Carcinoma
Advanced or Metastatic Gastric Cancer

Interventions: Drug: MRG003

First Posted Date: 2022-01-12

Last Posted Date: 2022-01-12

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 60

Registration Number: NCT05188209

Locations: 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China
🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

and more 2 locations

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Phase 1

Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Interventions: Drug: MRG001

First Posted Date: 2021-12-14

Last Posted Date: 2022-02-22

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 108

Registration Number: NCT05155839

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Harbin First Hospital, Harbin, Heilongjiang, China

and more 9 locations

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Phase 2

Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer
Locally Advanced Gastric Cancer

Interventions: Drug: MRG002

First Posted Date: 2021-12-02

Last Posted Date: 2022-02-23

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 60

Registration Number: NCT05141747

Locations: 🇨🇳
Shanghai Oriental Hospital, Shanghai, Shanghai, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Phase 2

Conditions: Non-small- Cell Lung Cancer (NSCLC)

Interventions: Drug: MRG002

First Posted Date: 2021-12-02

Last Posted Date: 2021-12-02

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 100

Registration Number: NCT05141786

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions: Drug: MRG003
Drug: Capecitabine tablets
Drug: Docetaxel injection

First Posted Date: 2021-11-19

Last Posted Date: 2023-04-26

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 238

Registration Number: NCT05126719

Locations: 🇨🇳
Zhongshan City People's Hospital, Zhongshan, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy